Nasdaq:VSEE
VSEE HEALTH, INC.
A clinical-stage biotech firm leveraging advanced antibody-drug conjugate technology to target solid tumors with a focus on improving patient outcomes.
Key Metrics
Investment Thesis
Bull Case
If clinical trials succeed for its lead assets, the company could unlock substantial value through milestone payments and royalties from partners, potentially turning the current loss into future profit.
Bear Case
With total liabilities matching total assets at $20.0M and a cash balance of only $326K, the company faces an immediate liquidity crisis requiring rapid capital raises or asset sales to survive.
About VSEE HEALTH, INC.
VSEE Health Inc. is a biotechnology company focused on developing next-generation therapies, primarily within the oncology space, serving markets in North America and internationally through its proprietary drug discovery platforms.
Analysis
Management Discussion
The company reported a significant net loss of $57.7M in 2024 compared to $-4.4M in 2023, driven by elevated operating expenses of $69.3M and a negative cash flow from operations of $5.8M.
Industry Overview
The biotechnology sector is currently characterized by high volatility where early-stage companies must navigate costly clinical trials while competing against established giants in oncology.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $10.4M |
| Cost of Revenue | $0 | $0 | $3.2M |
| Gross Profit | $0 | $0 | $7.2M |
| Operating Expenses | $3.6M | $2.6M | $69.3M |
| Operating Income | $-3.6M | $-2.6M | $-62.2M |
| G&A | — | — | $6.6M |
| Stock-Based Comp | — | — | $896.5K |
| D&A | — | — | $1.3M |
| Depreciation | — | — | $17.8K |
| Amortization | — | — | $1.1M |
| Other OpEx | — | — | $62.8M |
| Non-Operating Income | $539.7K | $-1.8M | $2.8M |
| Interest Income | $922.6K | $358.8K | — |
| Pre-Tax Income | $-3.1M | $-4.4M | $-59.3M |
| Income Tax | $187.2K | $0 | $-1.6M |
| Continuing Ops | $-3.2M | $-4.4M | $-57.7M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-3.2M | $-4.4M | $-57.7M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-3.2M | $-4.4M | $-57.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $107.0K | $1.9K | $3.0M |
| Cash & Equivalents | $107.0K | $1.9K | $326.1K |
| Accounts Receivable | — | — | $1.7M |
| Prepaid Expenses | — | — | $446.8K |
| Other Current Assets | $0 | $0 | $531.7K |
| Long-Term Assets | $7.5M | $1.4M | $17.0M |
| PP&E (Net) | — | — | $680.2K |
| Intangibles | — | — | $11.0M |
| Goodwill | — | — | $4.9M |
| Operating Leases | — | — | $379.6K |
| Other LT Assets | — | — | $0 |
| Total Assets | $7.6M | $1.4M | $20.0M |
| Current Liabilities | $3.3M | $8.0M | $19.0M |
| Accounts Payable | — | — | $4.3M |
| Current Debt | — | — | $434.0K |
| Current Leases | — | — | $72.8K |
| Deferred Revenue | — | — | $417.8K |
| Taxes Payable | $187.2K | $187.2K | — |
| Other Current Liab | $3.1M | $7.8M | $13.8M |
| Long-Term Liabilities | $4.4M | $4.4M | $1.0M |
| Long-Term Debt | — | — | $593.9K |
| LT Operating Leases | — | — | $269.3K |
| Other LT Liab | — | — | $67.4K |
| Total Liabilities | $7.7M | $12.4M | $20.0M |
| Shareholders' Equity | $-31.2K | $-11.0M | $-18.5K |
| Paid-In Capital | $293.0K | $550.2K | $67.7M |
| Retained Earnings | $-7.7M | $-12.8M | $-67.7M |
| Total L&E | $7.6M | $1.4M | $20.0M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-3.2M | $-4.4M | $-57.7M |
| Non-Cash Adjustments | $249.5K | $1.8M | $53.0M |
| Working Capital Changes | $1.6M | $1.6M | $-1.1M |
| Cash from Operations | $-1.4M | $-962.0K | $-5.8M |
| Capital Expenditures | — | — | $55.3K |
| Cash from Investing | $110.1M | $6.5M | $-26.1K |
| Share Buybacks | $110.5M | $6.8M | — |
| Cash from Financing | $-109.4M | $-5.7M | $6.0M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-653.0K | $-105.1K | $207.4K |
| Beginning Cash | $760.0K | $107.0K | $118.7K |
| Ending Cash | $107.0K | $1.9K | $326.1K |
Frequently Asked Questions
How does VSEE HEALTH, INC. make money?
Oncology Therapeutics (primary revenue driver via strategic partnerships), Biotechnology Services and Consulting, and Collaborative Research Agreements.
What are the main risks for VSEE?
Clinical trial failures or delays for key oncology assets, High cash burn rate exacerbated by operating losses and limited current liquidity, Dependence on external funding sources such as equity offerings or partnership milestones to sustain operations.
What is VSEE's competitive advantage?
Proprietary ADC platform enabling selective drug delivery to cancer cells, Strong pipeline of late-stage clinical candidates with differentiated mechanisms of action, and Strategic alliances providing upfront payments and milestone funding.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.